Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 274 | Osteogenesis Imperfecta | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-002553-38-ES (EUCTR) | 09/08/2013 | 09/04/2013 | Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfecta | Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfecta - TERCELOI | Osteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.;Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04] | Product Name: celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida Product Code: REF CRUZADA PEI Nº 12-088 INN or Proposed INN: células mesenquimales troncales adultas alogénicas de médula ósea no expandidas Other descriptive name: células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | Itziar Astigarraga Aguirre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain |